Holen Sie sich die Stockscreener-App
11.09
2.78%
0.30
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Indaptus Therapeutics (INDP) Secures $2.3M Through Convertible N - GuruFocus
Indaptus Therapeutics raises $2.3 million through convertible notes By Investing.com - Investing.com South Africa
Indaptus Therapeutics Announces Sale Of $2.3 Million In Private Placement Of Convertible Notes And Warrants - MarketScreener
Indaptus Therapeutics Completes $2.3M Private Placement - TipRanks
Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round - Nasdaq
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - The Manila Times
Bitcoin Depot Adds to Bitcoin Treasury Holdings Amid Continued Market Momentum - The Manila Times
Clinical-Stage Biotech Indaptus Raises $2.3M from Healthcare Investor to Advance Cancer Treatment Trials - Stock Titan
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Breakthrough Pediatric Cancer Drug Could Unlock $155M FDA Voucher as OS Therapies Pursues RMAT Status - Stock Titan
Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan
Estrella's $3.35M Funding Accelerates Novel T-Cell Therapy Trial for Non-Hodgkin's Lymphoma - Stock Titan
INDP stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com India
Indaptus Therapeutics (INDP) Advances Clinical Trial with Decoy2 - GuruFocus
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors - Stock Titan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
BNY Mellon Credit Fund's Last Distribution: $2.00 Payout Coming Before August Liquidation - Stock Titan
Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus
INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus
Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView
Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView
Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference - Stock Titan
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference - Stock Titan
Loar Holdings Q1 2025 Earnings Call: How to Join the May 13 Investor Presentation - Stock Titan
Luminar Reveals Major Business Overhaul: Strategic Restructuring and Cost Cuts Coming with Q1 Earnings - Stock Titan
Mark Your Calendar: Millrose Properties Q1 2025 Earnings Coming May 14Key Details Here - Stock Titan
Sandisk Key Q3 Financial Results: How to Access the May 7 Earnings Call - Stock Titan
Healthcare Giant Concentra's $55M Pivot Deal Adds 200 Workplace Clinics Across 40 States - Stock Titan
BeiGene Earnings Preview: Q1 Results Coming May 7 as Company Transforms to BeOne Medicines - Stock Titan
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World
Claritev Earnings Preview: Q1 2025 Results Coming May 8What to Watch - Stock Titan
Fortune 500 Retail Giant QVC Group Sets Stage for Crucial Q1 2025 Earnings Reveal - Stock Titan
Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times
Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan
$1 Million Winner: Berkshire Employee Nails 31 of 32 March Madness Picks - Stock Titan
Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com
Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com
Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India
Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan
Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia
CERo Therapeutics Locks Critical Manufacturing Partner for Groundbreaking Leukemia Treatment Trial - Stock Titan
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):